225 Second Avenue
About BioverativLaunching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.
CEO: John Cox
65 articles with Bioverativ
BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A
Early data (n=2) show an unprecedented half-life of 44 hours with a single 65 IU/kg dose of BIVV001, significantly longer than the half-life observed with a short-acting recombinant factor VIII therapy
New Data at ASH Showcase Bioverativ’s Commitment to Transforming Care for People with Hemophilia and Other Rare Blood Disorders
An oral presentation on BIVV001, an investigational and potentially transformative von Willebrand-independent factor VIII therapy for people with hemophilia A will be given
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
8/14/2018A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company.
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis
New study is first to identify an increased risk of death in people with cold agglutinin disease compared to the general population
Sarissa Capital Management LP today made the following statement regarding Ironwood Pharmaceuticals, Inc.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. Venture capital (VC) firms are on the alert for this type of thing (and vice versa).
Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A
BIVV001 demonstrates unprecedented half-life of 37 hours with high factor VIII activity of 5.6% at seven days following a single low dose in late-breaking presentation at WFH 2018 World Congress Bioverativ is now exploring twice-a-month dosing with BIVV001, which could transform the treatment paradigm in hemophilia A
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
BIVV003 is a gene-edited cell therapy candidate for the treatment of people with sickle cell disease
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.